[
    "{\"step_by_step_thinking\": \"First, I need to understand what first-line single-agent mitoxantrone treatment is. From Document [1], I learned that it is a treatment method for high-risk metastatic breast cancer patients. The document also mentions a study that found no significant difference in terms of response, remission rate, remission duration, time to response, time to best response, time to progression or overall survival between single-agent treatment with mitoxantrone and combination treatment with fluorouracil, epirubicin and cyclophosphamide. However, the single-agent treatment arm had a significant difference in gain from treatment using a modified Brunner's score, favoring the single-agent treatment arm. This suggests that single-agent mitoxantrone treatment may be as effective as combination chemotherapy. However, Document [22] suggests that combination chemotherapy has a higher response rate and a higher risk of febrile neutropenia in metastatic breast cancer. There is no difference in overall survival time between these treatment strategies. This suggests that while single-agent mitoxantrone treatment may be as effective as combination chemotherapy in some aspects, it may not be as effective in others. Therefore, the answer is maybe.\", \"answer_choice\": \"C\"}"
]